Predictors of improvement and progression of diabetic polyneuropathy following treatment with alpha-lipoic acid for 4 years in the NATHAN 1 trial
injections of 100 nmol kg 1 MK-801 ( n = 7-8 mice), 100 nmol kg 1 GLP-1 ( n = 8 mice), 100 nmol kg 1 GLP-1MK-801 ( n = 8 mice) or vehicle (isotonic saline, n = 8 mice) for 14 days
Finan B, Ma T, Ottaway N, et al
With the right tools, the right support, and a commitment to yourself, you can achieve amazing things
Important Notice This product is intended for laboratory research use only
3 Currently, semaglutide, which was originally developed for managing type 2 diabetes, is now being used to treat obesity, and has proven to be highly effective, particularly in obese patients without diabetes